Published in J Med Chem on December 05, 2002
Rapid, stable, chemoselective labeling of thiols with Julia-Kocieński-like reagents: a serum-stable alternative to maleimide-based protein conjugation. Angew Chem Int Ed Engl (2013) 1.85
Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol (2007) 1.26
Protein nanocapsules containing doxorubicin as a pH-responsive delivery system. Small (2011) 1.07
Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides. J Biol Chem (2010) 1.03
Degradable conjugates from oxanorbornadiene reagents. J Am Chem Soc (2012) 1.03
Isomerization/Recyclization of some 5-Ethoxycarbonyl-pyrimidines. J Heterocycl Chem (2005) 0.90
INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs (2009) 0.90
Visible Light Controlled Release of Anticancer Drug through Double Activation of Prodrug. ACS Med Chem Lett (2012) 0.88
Thermal targeting of an acid-sensitive doxorubicin conjugate of elastin-like polypeptide enhances the therapeutic efficacy compared with the parent compound in vivo. Mol Cancer Ther (2012) 0.87
Conjugation of organoruthenium(II) 3-(1H-benzimidazol-2-yl)pyrazolo[3,4-b]pyridines and indolo[3,2-d]benzazepines to recombinant human serum albumin: a strategy to enhance cytotoxicity in cancer cells. Inorg Chem (2011) 0.85
Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem Soc Rev (2016) 0.84
Albumin-binding and tumor vasculature determine the antitumor effect of 15-deoxy-Delta-(12,14)-prostaglandin-J(2) in vivo. Neoplasia (2009) 0.83
Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther (2016) 0.82
Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review). Int J Oncol (2012) 0.82
Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma. Neoplasia (2014) 0.81
Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Invest New Drugs (2014) 0.81
Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate. Cancer Biother Radiopharm (2011) 0.80
Cell penetrating peptides fused to a thermally targeted biopolymer drug carrier improve the delivery and antitumor efficacy of an acid-sensitive doxorubicin derivative. Int J Pharm (2012) 0.80
Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model. Invest New Drugs (2011) 0.80
Co-opting biology to deliver drugs. Biotechnol Bioeng (2014) 0.79
Engineered drug-protein nanoparticle complexes for folate receptor targeting. Biochem Eng J (2014) 0.79
Biological evaluation of protein nanocapsules containing doxorubicin. Int J Nanomedicine (2013) 0.79
Optimization of an albumin-binding prodrug of Doxorubicin that is cleaved by prostate-specific antigen. ACS Med Chem Lett (2010) 0.78
Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors. Invest New Drugs (2015) 0.77
Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3. J Cancer Ther (2012) 0.77
Tissue distribution and tumor uptake of folate receptor-targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration. Acta Pharm Sin B (2016) 0.75
Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers. Chem Sci (2017) 0.75
An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo. Chem Sci (2016) 0.75
Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549). Chem Biol Drug Des (2016) 0.75
Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549). Drug Des Devel Ther (2016) 0.75
Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole. J Cancer Res Ther Oncol (2014) 0.75
Synthesis and characterization of novel bioactive 1,2,4-oxadiazole natural product analogs bearing the N-phenylmaleimide and N-phenylsuccinimide moieties. Beilstein J Org Chem (2013) 0.75
Advances in sarcoma diagnostics and treatment. Oncotarget (2016) 0.75
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 4.00
MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med (2008) 3.00
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res (2012) 2.78
Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest (2011) 2.25
Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins (2004) 2.12
Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst (2011) 2.11
Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. Eur Urol (2008) 2.06
Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chem Biol (2011) 2.05
Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets? Proteins (2003) 1.93
Optimizing fragment and scaffold docking by use of molecular interaction fingerprints. J Chem Inf Model (2007) 1.87
S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell (2011) 1.71
Tautomerism in computer-aided drug design. J Recept Signal Transduct Res (2003) 1.70
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol (2005) 1.69
Prodrug strategies in anticancer chemotherapy. ChemMedChem (2008) 1.62
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study. Onkologie (2007) 1.60
Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat Cell Biol (2008) 1.60
Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. J Med Chem (2008) 1.59
A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterology (2009) 1.52
Thermodynamics of protein-ligand interactions: history, presence, and future aspects. J Recept Signal Transduct Res (2004) 1.50
A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins (2006) 1.48
sc-PDB: an annotated database of druggable binding sites from the Protein Data Bank. J Chem Inf Model (2006) 1.47
sc-PDB: a database for identifying variations and multiplicity of 'druggable' binding sites in proteins. Bioinformatics (2011) 1.46
Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer. Cancer Biol Ther (2011) 1.45
Phase II STUdy with 3rd- or 4th-line bendamustine (flat dose) therapy in patients with metastatic breast cancer. Onkologie (2009) 1.44
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer (2005) 1.42
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res (2005) 1.33
Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther (2005) 1.33
Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia (2004) 1.33
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res (2009) 1.32
Calpain-1 regulates Bax and subsequent Smac-dependent caspase-3 activation in neutrophil apoptosis. J Biol Chem (2003) 1.31
Temporal expression of adhesion factors and activity of global regulators during establishment of Staphylococcus aureus nasal colonization. J Infect Dis (2010) 1.30
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res (2005) 1.28
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer (2002) 1.26
Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J Biol Chem (2011) 1.25
Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. J Med Chem (2007) 1.23
Delineating a Ca2+ binding pocket within the venus flytrap module of the human calcium-sensing receptor. J Biol Chem (2005) 1.22
Prefrontal cortex modulates placebo analgesia. Pain (2009) 1.21
Molecular modeling of the second extracellular loop of G-protein coupled receptors and its implication on structure-based virtual screening. Proteins (2008) 1.20
Recovering the true targets of specific ligands by virtual screening of the protein data bank. Proteins (2004) 1.20
Alignment-free ultra-high-throughput comparison of druggable protein-ligand binding sites. J Chem Inf Model (2010) 1.20
Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca(2+)-sensing receptor. J Biol Chem (2003) 1.19
Positive and negative allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J Biol Chem (2004) 1.19
Ranking targets in structure-based virtual screening of three-dimensional protein libraries: methods and problems. J Chem Inf Model (2008) 1.17
Functional characterization of sonic hedgehog mutations associated with holoprosencephaly. J Biol Chem (2004) 1.16
DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res (2009) 1.15
Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res (2004) 1.15
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol (2005) 1.13
Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol (2005) 1.12
Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res (2007) 1.12
Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg (2009) 1.10
Spectroscopic ellipsometry and polarimetry for materials and systems analysis at the nanometer scale: state-of-the-art, potential, and perspectives. J Nanopart Res (2009) 1.09
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res (2004) 1.09
Binding mode prediction of cytochrome p450 and thymidine kinase protein-ligand complexes by consideration of water and rescoring in automated docking. J Med Chem (2005) 1.07
Customizing G Protein-coupled receptor models for structure-based virtual screening. Curr Pharm Des (2009) 1.06
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol (2004) 1.05
Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat (2003) 1.05
High-level expression and purification of human thymidine kinase 1: quaternary structure, stability, and kinetics. Protein Expr Purif (2006) 1.05
High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. Int J Cancer (2011) 1.04
Molecular determinants of non-competitive antagonist binding to the mouse GPRC6A receptor. Cell Calcium (2009) 1.03
Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica (2009) 1.03
High-throughput modeling of human G-protein coupled receptors: amino acid sequence alignment, three-dimensional model building, and receptor library screening. J Chem Inf Comput Sci (2004) 1.03
Structure-based discovery of allosteric modulators of two related class B G-protein-coupled receptors. ChemMedChem (2011) 1.02
Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia (2011) 1.02
Assessing the scaffold diversity of screening libraries. J Chem Inf Model (2006) 1.02
A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res (2003) 1.02
Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther (2012) 1.02
Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. Clin Cancer Res (2010) 1.02
Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am J Physiol Cell Physiol (2006) 1.01
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs (2010) 1.01
Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT. Cancer Lett (2007) 1.01
Biomarkers in tumor angiogenesis and anti-angiogenic therapy. Int J Mol Sci (2011) 1.01
The crystal structure of PfFabZ, the unique beta-hydroxyacyl-ACP dehydratase involved in fatty acid biosynthesis of Plasmodium falciparum. Protein Sci (2005) 1.00
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. Cancer Immunol Immunother (2005) 0.99
Development and validation of a novel protein-ligand fingerprint to mine chemogenomic space: application to G protein-coupled receptors and their ligands. J Chem Inf Model (2009) 0.99
A simple and fuzzy method to align and compare druggable ligand-binding sites. Proteins (2008) 0.99
N-glycan structures and N-glycosylation sites of mouse soluble intercellular adhesion molecule-1 revealed by MALDI-TOF and FTICR mass spectrometry. Glycobiology (2006) 0.98
Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis (2007) 0.98
Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Mol Cancer Ther (2002) 0.97
Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. J Med Chem (2003) 0.97
Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand profiling. J Chem Inf Model (2012) 0.96
Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems. J Control Release (2012) 0.96
Increase in fluidity in the membrane of MT3 breast cancer cells correlates with enhanced cell adhesion in vitro and increased lung metastasis in NOD/SCID mice. Arch Biochem Biophys (2006) 0.96
Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? Eur J Cardiothorac Surg (2011) 0.96
Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer. Pancreas (2009) 0.96